Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13499
Abstract: Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front‐line setting and as later‐line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population‐based level… read more here.
Keywords: real world; lymphocytic leukemia; outcomes 205; world outcomes ... See more keywords